🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

86 results for “TG” Clear

  1. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  2. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  3. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  4. KB105

    Krystal Biotech Netherlands B.V.

    TGM-1 Related Autosomal Recessive Congenital Ichthyosis

    phase 2 mab active

    1 trial

  5. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  6. NBP Softgel Capsules

    NovaBridge Biosciences

    AIS

    phase 2 small molecule completed

    1 trial

  7. PTG-100

    Protagonist Therapeutics, Inc

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  8. PTG-300

    Protagonist Therapeutics, Inc

    β-thalassemia

    phase 2 small molecule completed

    2 trials

  9. PTG-300

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 2 small molecule completed

    2 trials

  10. PTG-300

    Protagonist Therapeutics, Inc

    Hereditary Hemochromatosis

    phase 2 small molecule completed

    1 trial

  11. PTG-CARCIK-CD19

    Fondazione Telethon ETS

    B cell precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  12. PTG-CARCIK-CD19

    Fondazione Telethon ETS

    B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  14. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  15. SODIUM CHLORIDE SOLUTION 0.9%

    Pharma Mar S.A.

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  16. TG-0054

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  17. TG-0054 (2.24 mg/kg)

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  18. TG-0054 combined with G-CSF

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  19. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  20. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  21. TGRX-326

    China SXT Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  23. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  24. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources